Hologic, Inc. provided earnings guidance for the third quarter of fiscal 2024. For the quarter, the Company expects revenues of $992.5 million to $1,007.5 million and GAAP EPS of $0.80 to $0.87.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
75.06 USD | +0.14% | -0.17% | +4.98% |
May. 09 | Argus Adjusts Price Target on Hologic to $95 From $89 | MT |
May. 06 | Lumos Diagnostics Concludes Initial Phase of Development Deal with Hologic for Fetal Fibronectin Test; Shares Jump 6% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.98% | 17.49B | |
+12.09% | 228B | |
+14.81% | 196B | |
+18.16% | 141B | |
+28.86% | 110B | |
+0.53% | 65.88B | |
+16.89% | 54.3B | |
+6.33% | 52.39B | |
+10.99% | 45.22B | |
+5.72% | 37.12B |
- Stock Market
- Equities
- HOLX Stock
- News Hologic, Inc.
- Hologic, Inc. Provides Earnings Guidance for the Third Quarter of Fiscal 2024